| Friday, March 27 |
|
3:00 - 7:30 PM
|
Registration
|
Foyer
|
|
6:30 - 7:30 PM
|
Refreshments
|
Foyer
|
|
7:30 - 8:30 PM
|
Keynote Address (Joint)
|
Sea to Sky Ballroom B,C
|
|
|
|
|
*
James D. Marks,
University of California, San Francisco
|
|
|
*
Barbara L. Weber,
GlaxoSmithKline
|
|
|
|
|
|
David P. Lane,
Experimental Therapeutic Centre
Target Validation in Cancer Treatment: The Use of Chemical Biology and Protein Aptamer Approaches
|
|
| Saturday, March 28 |
|
7:00 - 8:00 AM
|
Breakfast
|
Sea to Sky Ballroom A, Lower Level
|
|
7:00 - 8:00 AM
|
Poster Setup
|
Foyer/Mountain View/Sea to Sky Ballroom A
|
|
8:00 - 11:15 AM
|
Novel Cancer Drug Scaffolds (Joint)
|
Sea to Sky Ballroom B,C
|
|
*
James E. Bradner,
Dana-Farber Cancer Institute
|
|
|
*
James D. Marks,
University of California, San Francisco
|
|
|
Andreas G. Plückthun,
University of Zürich
Ankyrin Repeat Proteins
|
|
|
|
|
|
Nick Terrett,
Ensemble Discovery Corporation
A DNA-Programmed Chemistry Approach to Macrocyclic Lead Compounds
|
|
|
|
|
|
Gregory L. Verdine,
Harvard University
Drugging “Undruggable” Targets Using Stapled Peptides
|
|
|
|
|
|
Rodney W. Lappe,
CovX Research LLC
Using CovX-Body Technology to Target the Angiopoietin Axis
|
|
|
Yollete V. Guillen Schlippe,
Massachusetts General Hospital
Short Talk: Selection of Cyclic Peptides Composed of Multiple Unnatural Amino Acids that Display Antibody-Like Affinity
|
|
|
Jennifer R. Cochran,
Stanford University
Short Talk: Engineered Knottin Peptides: A New Class of Agents for Imaging Integrin Expression in Living Subjects
|
|
|
9:20 - 9:40 AM
|
Coffee Break
|
Foyer
|
|
11:15 AM - 12:00 PM
|
Lunch
|
Foyer/Sea to Sky Ballroom A
|
|
12:00 - 2:30 PM
|
Poster Session 1
|
Foyer/Mountain View/Sea to Sky Ballroom A
|
|
2:30 - 4:30 PM
|
Workshop 1: Novel Approaches to Cancer Drug Development (Joint)
|
Sea to Sky Ballroom C
|
|
*
Louis M. Weiner,
Georgetown University Medical Center
|
|
|
Steve K. Horrigan,
Avalon Pharmaceuticals
Systems Biology for Lead Optimization
|
|
|
Lutz Jermutus,
MedImmune Ltd
Discovering Cancer Therapeutics by Phage and Ribosome Display as well as Transgenics Technologies
|
|
|
Ravindra Majeti,
Stanford University
Blocking Monoclonal Antibodies Directed Against CD47 Preferentially Enable Phagocytosis and Elimination of Human Acute Myeloid Leukemia Stem Cells
|
|
|
Teemu T. Junttila,
Genentech
Superior in vivo Efficacy of Afucosylated Trastuzumab in the Treatment of HER2 Amplified Breast Cancer
|
|
|
Mariia Yuneva,
University of California, San Francisco
Combining Metabolomics with Microarray Analysis to Determine Metabolic Cancer Targets in vivo
|
|
|
4:30 - 5:00 PM
|
Coffee Available
|
Foyer
|
|
5:00 - 7:00 PM
|
Generating and Engineering Novel Antibody Binding Sites
|
Sea to Sky Ballroom B
|
|
*
Lutz Jermutus,
MedImmune Ltd
|
|
|
George Georgiou,
University Of Texas At Austin
Selection, Fc Engineering and Preparative Expression of Full Length IgG in E.coli
|
|
|
James D. Marks,
University of California, San Francisco
Selecting Internalizing Antibodies for Drug Delivery
|
|
|
|
|
|
Max Woisetschlager,
f-star
Antigen Binding by Modified Immunoglobulin Fc (Fcab) and Complete IgGs with Additional Binding Sites
|
|
|
|
|
|
Roger R. Beerli,
Cytos Biotechnology AG
Short Talk: Isolation and Preclinical Validation of Therapeutic Human Monoclonal Antibodies Isolated by Mammalian Cell Display
|
|
|
7:00 PM -
|
On Own for Dinner
|
|
| Sunday, March 29 |
|
7:00 - 8:00 AM
|
Breakfast
|
Sea to Sky Ballroom A, Lower Level
|
|
8:00 - 11:15 AM
|
Engineering Fc Regions for Optimized ADCC and PK
|
Sea to Sky Ballroom B
|
|
*
Raphael Clynes,
Columbia University
|
|
|
|
|
|
|
|
|
Louis M. Weiner,
Georgetown University Medical Center
Optimizing in vitro and in vivo ADCC for Cancer Therapy
|
|
|
John R. Desjarlais,
Xencor
Engineered Fc Domains for Enhanced Cytotoxicity and Pharmacokinetics
|
|
|
Pablo Umaña,
GlycArt Biotechnology AG
New Glycoengineered Antibodies with Enhanced Effector Functions
|
|
|
E. Sally Ward,
University of Texas Southwestern Medical Center
The Role of FcRn in IgG Homeostasis: Implications for the Use of Antibodies in Therapy
|
|
|
|
|
|
Shu-ichi Hashimoto,
Chiome Bioscience Inc.
Short Talk: ADLib System: New Antibody Generating Technology based on Cell Surface Displayed Antibody Library
|
|
|
Jeanette H.W. Leusen,
University Medical Center, Utrecht
Short Talk: The Fc Receptor gamma-Chain ITAM is Required for Antibody Immunotherapy
|
|
|
|
|
|
9:20 - 9:40 AM
|
Coffee Break
|
Foyer
|
|
11:15 AM -
|
On Own for Lunch
|
|
|
11:15 AM - 1:00 PM
|
Poster Setup
|
Foyer/Mountain View/Sea to Sky Ballroom A
|
|
1:00 - 10:00 PM
|
Poster Viewing
|
Foyer/Mountain View/Sea to Sky Ballroom A
|
|
2:30 - 4:30 PM
|
Workshop 2: Bispecific Antibodies and Antibody Combinations: The How and the Why
|
Sea to Sky Ballroom B
|
|
*
James D. Marks,
University of California, San Francisco
|
|
|
Robert Mabry,
ZymoGenetics, Inc.
Selection of Stable Antibody Fragments for Assembly of Dual-Targeting Therapeutics
|
|
|
Carston R. Wagner,
University of Minnesota
Chemically Controlled Assembly of Single-Chain Antibody Nanorings
|
|
|
Wei Yan,
Amgen Inc.
Design and Engineering of Fc Heterodimers for the Production of Bispecific Antibodies
|
|
|
Aran Frank Labrijn,
Genmab
Therapeutic IgG4 Antibodies Engage in Fab-Arm Exchange with Patient’s IgG4 in vivo
|
|
|
Ann P. MacLaren,
Biogen Idec
A Novel Tetravalent Anti-CD23 Antibody Induces Potent Anti-Tumor Activity in CD23+ Tumor Cells via Hyper Cross-Linking of CD23
|
|
|
Klaus Koefoed,
Symphogen A/S
Development of Sym004 - a Dual Antibody Combination Targeting the Epidermal Growth Factor Receptor with Strong Anti-Tumor Efficacy in a Xenograft Mouse Model
|
|
|
Rob C. Roovers,
Utrecht University
Combining Different Modes of EGFR Inhibition into a Single Nanobody-Based Molecule Yields a Promising Anti-Cancer Drug
|
|
|
4:30 - 5:00 PM
|
Coffee Available
|
Foyer
|
|
5:00 - 7:00 PM
|
Immune System Activation to Elicit Therapeutic Responses
|
Sea to Sky Ballroom B
|
|
*
E. Sally Ward,
University of Texas Southwestern Medical Center
|
|
|
Raphael Clynes,
Columbia University
Conversion of Passive Antibody Therapy to Active Immunity
|
|
|
|
|
|
Gerard Zurawski,
Baylor Institute for Immunology Research
Vaccines Based on Targeting Antigens Directly to DCs
|
|
|
|
|
|
Kavita Dhodapkar,
Yale University
Antibody-Based Induction of Adaptive Immune Response
|
|
|
Mark S. Cragg,
Cancer Sciences Division
Short Talk: The Role of Activatory and Inhibitory FcgR in Antibody Immunotherapy
|
|
|
7:00 - 8:00 PM
|
Social Hour w/ Lite Bites
|
Foyer/Mountain View/Sea to Sky Ballroom A
|
|
7:30 - 10:00 PM
|
Poster Session 2
|
Foyer/Mountain View/Sea to Sky Ballroom A
|
| Monday, March 30 |
|
7:00 - 8:00 AM
|
Breakfast
|
Sea to Sky Ballroom A, Lower Level
|
|
8:00 - 11:15 AM
|
Antibodies for Treatment of Cancer
|
Sea to Sky Ballroom B
|
|
*
Louis M. Weiner,
Georgetown University Medical Center
|
|
|
Mark X. Sliwkowski,
Genentech, Inc.
HER2 Targeted Therapies
|
|
|
Andrew M. Scott,
Ludwig Institute for Cancer Research
Targeting a Novel EGFR Epitope on Cancer Cells
|
|
|
Kerry Chester,
Antibody-Directed Enzyme Prodrug Therapy (ADEPT) of Cancer
|
|
|
Philip E. Thorpe,
University of Texas Southwestern Medical Center
Targeting Exposed Phosphatidylserine on Cancer Blood Vessels: Preclinical and Clinical Studies
|
|
|
Kelly J. Davis,
Massachusetts Institute of Technology
Short Talk: Antibody with Picomolar Affinity to DOTA Chelates of Multiple Radionuclides for Pretargeted Radioimmunotherapy
|
|
|
Mitsuo Satoh,
Research Division, Kyowa Hakko Kirin Company Ltd.
Short Talk: Non-Fucosylated Rituximab Potentiates Human Neutrophil Phagocytosis through its High Binding for FcgammaRIIIb and MHC Class II Expression on the Phagocytotic Neutrophils
|
|
|
9:20 - 9:40 AM
|
Coffee Break
|
Foyer
|
|
11:15 AM - 1:00 PM
|
Poster Setup
|
Foyer/Mountain View/Sea to Sky Ballroom A
|
|
11:15 AM -
|
On Own for Lunch
|
|
|
1:00 - 10:00 PM
|
Poster Viewing
|
Foyer/Mountain View/Sea to Sky Ballroom A
|
|
2:30 - 4:30 PM
|
Workshop 3: Therapeutic Antibodies in the Neurosciences
|
Sea to Sky Ballroom B
|
|
*
Eric V. Shusta,
University of Wisconsin, Madison
Antibodies and the Blood-Brain Barrier
|
|
|
Anne Messer,
Wadsworth Center
Intrabodies for Neurodegeneration Disorders
|
|
|
|
|
|
Anthony Williamson,
Calmune Corporation
Antibodies for Prion Based Diseases
|
|
|
Angela R. Jones,
University of Wisconsin - Madison
Short Talk: Identification of Blood-Brain Barrier Targeting and Transporting Antibodies
|
|
|
4:30 - 5:00 PM
|
Coffee Available
|
Foyer
|
|
5:00 - 7:00 PM
|
Identifying and Predicting Antibody Efficacy and Toxicity
|
Sea to Sky Ballroom B
|
|
*
Andrew M. Scott,
Ludwig Institute for Cancer Research
|
|
|
Peter D. Senter,
Seattle Genetics Inc.
Antibody Drug Conjugates for Cancer Therapy
|
|
|
|
|
|
Birgit Schoeberl,
Merrimack Pharmaceuticals
An Attempt to Translate in vitro Responses into the Clinic Using Computationally Predicted Preclinical Data from ErbB Targeted Therapies
|
|
|
Richard H.J. Begent,
University College London
Guidelines for Information about Antibody Therapy Experiments; Lessons from the Tegenero Experience
|
|
|
Max Warncke,
Novartis
Short Talk: Effector Functions of Human IgG Subclasses for Non-Human Primate FcgR
|
|
|
7:00 - 8:00 PM
|
Social Hour w/ Lite Bites
|
Foyer/Mountain View/Sea to Sky Ballroom A
|
|
7:30 - 10:00 PM
|
Poster Session 3
|
Foyer/Mountain View/Sea to Sky Ballroom A
|
| Tuesday, March 31 |
|
7:00 - 8:00 AM
|
Breakfast
|
Sea to Sky Ballroom A, Lower Level
|
|
8:00 - 11:15 AM
|
Antibodies in the Treatment of Autoimmunity, Allergy and Infectious Diseases
|
Sea to Sky Ballroom B
|
|
*
James D. Marks,
University of California, San Francisco
|
|
|
Ian A. Wilson,
The Scripps Research Institute
Structural Aspects of Antibody Recognition of Influenza
|
|
|
Antonio Lanzavecchia,
Institute for Research in Biomedicine
Human Monoclonal Antibodies from Memory B cells
|
|
|
Dennis R. Burton,
The Scripps Research Institute
Antibodies for HIV Therapy and Vaccine Development
|
|
|
John Haurum,
Imclone
Capturing the Natural Humoral Immune Response by Symplex
|
|
|
Tariq Ghayur,
Abbott Bioresearch Center
Dual Variable Domain Immunoglobulins (DVD-Ig TM): A Novel Class of Dual-Specific Biologics
|
|
|
9:20 - 9:40 AM
|
Coffee Break
|
Foyer
|
|
11:15 AM -
|
On Own for Lunch
|
|
|
4:30 - 5:00 PM
|
Coffee Available
|
Foyer
|
|
5:00 - 7:00 PM
|
Imaging in Cancer Drug Discovery (Joint)
|
Sea to Sky Ballroom B,C
|
|
*
E. Sally Ward,
University of Texas Southwestern Medical Center
|
|
|
*
Roger Y. Tsien,
University of California, San Diego
Optical and MR Imaging of Tumors in vivo with Activatable Cell Penetrating Peptides
|
|
|
Karl Dane Wittrup,
Massachusetts Institute of Technology
Pretargeted Radioimmunotherapy: Predictive Modeling and Experimental Validation
|
|
|
Anna M. Wu,
University of California, Los Angeles
Engineered Antibodies for Probing Cell Surface Markers in vivo
|
|
|
Sripad Ram,
University of Texas Southwestern Medical Center
Short Talk: 3D Single Molecule Tracking of Antibodies in Live Cells Using Multifocal Plane Microscopy
|
|
|
7:00 - 8:00 PM
|
Social Hour w/ Lite Bites
|
Foyer/Mountain View/Sea to Sky Ballroom A
|
|
8:00 - 11:00 PM
|
Entertainment
|
Foyer/Mountain View/Sea to Sky Ballroom A
|
| Wednesday, April 1 |
|
|
Departure
|
|
